Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Ascletis Pharma, Inc. ( (HK:1672) ) has shared an announcement.
Ascletis Pharma Inc. has proposed the adoption of the 2025 Share Option Scheme and the 2025 Share Award Scheme to align with new amendments to Chapter 17 of the Listing Rules effective from January 1, 2023. This move aims to offer incentives to attract and retain valuable talent crucial for the company’s development. The adoption of these schemes is subject to shareholder approval, and upon adoption, the existing share option scheme will be terminated. This strategic decision underscores Ascletis’s commitment to maintaining competitive compensation structures and supporting its long-term growth objectives.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focused on discovering, developing, and commercializing innovative drugs for the global market.
YTD Price Performance: 5.65%
Average Trading Volume: 2,379,310
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: HK$2.88B
See more insights into 1672 stock on TipRanks’ Stock Analysis page.
